Tucked in the Trump administration’s sweeping AI action plan announced Wednesday is a recommendation that tech companies with federal contracts ensure their models don’t include “ideological bias.” ...

Insiders tell CNN the FDA’s AI is “hallucinating” studies and can’t access key documents. Agency leaders insist the AI is ...

While “The Late Show” host Stephen Colbert was on his usual mid-summer vacation earlier this month, CBS executives weighed ...

Treasury Secretary Scott Bessent said Monday he believes the Federal Reserve system should be reviewed for potentially ...

Deep learning using multimodal MRI can distinguish Parkinson’s disease from multiple system atrophy with high accuracy, ...

With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.

The Trump administration on Wednesday unveiled its AI action plan, a package of initiatives and policy recommendations meant to cement the United States as a global leader in a technology that’s ...

Despite ambitions to streamline regulatory review, FDA’s Elsa platform has been prone to hallucinations, prompting internal scrutiny and questions about AI reliability and governance.

Machines are rapidly gaining the ability to perceive, interpret and interact with the visual world in ways that were once ...

People awoke from water rushing around them during the early morning hours of July 4, all along the Guadalupe River in the ...

"Buy now, pay later"users may hurt their credit if they don't pay back those loans on time. Credit score overseer Fair Isaac FICO announced new scoring models last month that will evaluate BNPL usage ...

The FDA's 'Elsa' AI, intended to speed up drug approvals, is reportedly fabricating studies, part of a wider trend of unreliable AI in high-stakes roles.